Ultra-High Sensitivity ESR1 Mutation Detection in Breast Cancer Research

The QuantideX® qPCR ESR1 exoMutation Kit (RUO) is a multi-analyte liquid biopsy assay designed for highly sensitive detection of the 11 most prevalent ESR1 mutations in plasma. Combining cell-free DNA (cfDNA) and exosomal RNA (exoRNA) analysis, this innovative approach enhances ESR1 mutation detection beyond conventional cfDNA-only testing.

Developed by Asuragen, a Bio-Techne brand, the assay uses established qPCR technology alongside the ExoLution™ Plus cfDNA + exoRNA Isolation Kit to support sensitive, minimally invasive biomarker detection in breast cancer research.

Complete QuantideX®qPCR ESR1 Workflow in a Single Day

The QuantideX®qPCR ESR1 exoMutation Kit provides all the reagents including buffers, enzymes, and positive and negative controls necessary for 50 RT-qPCR reactions and 50 isolations of both cfDNA and exosomal RNA, completed in less than 6 hours.

 

ESR1 Mutations and Treatment Resistance in HR+ mBC

The ESR1 gene encodes for estrogen receptor alpha (ERα), and mutations in its ligand-binding domain result in constitutive activation of the estrogen receptor, causing overactive downstream signalling. ESR1 mutations have emerged as a key biomarker in determining resistance to therapy in hormone receptor-positive (HR+), metastatic breast cancer (mBC) patients. While these mutations are exceptionally rare in treatment-naive patients, they are prevalent in up to 40% of mBC patients with prolonged exposure to endocrine therapy (ET) and lead to treatment failure and ultimately, disease progression. Recent and ongoing clinical trials aim to demonstrate that changing therapy at the first appearance of ESR1 mutations results in marked improvements in reduction of disease progression. Emerging novel therapies targeting ESR1-mutant disease offer a promising solution to overcoming this mechanism of primary therapy resistance.

Leveraging Exosomes for a Differentiated Approach

Whereas cfDNA is released exclusively from dying cells and is in relatively low abundance, all living cells actively secrete tens of thousands of exosomes every day releasing a great abundance of biological material into bodily fluids. Exosomes contain exosomal RNA, which provides a dynamic snapshot of the body’s transcriptome. By co-analysing exoRNA with cfDNA via liquid biopsy, we can unlock highly sensitive, minimally invasive biomarker detection using established qPCR testing technologies.

Utilising this approach, Asuragen has developed the first multi-analyte qPCR-based liquid biopsy assay for the detection of ESR1 mutations from plasma, empowering molecular laboratories to participate in this new frontier of clinical research and push the boundaries of conventional qPCR.

 

The addition of Exosomal RNA (exoRNA) boosts the sensitivity of the ESR1 signal by ~60% over cfDNA alone

 

 

Figure 1. cfDNA and exoRNA distribution across 15 normal female plasma samples shows an increase in ESR1 copies due to exoRNA using two different sample collection tubes.

Complete QuantideX®qPCR ESR1 Workflow in a Single Day

The QuantideX®qPCR ESR1 exoMutation Kit is paired with the ExoLution™ Plus cfDNA + exoRNA Isolation Kit, leveraging proprietary chemistries to co-isolate cfDNA + exoRNA in a single workflow. ExoLution Plus includes all necessary reagents and consumables for high-quality multianalyte isolation to power downstream mutation testing.

 

Figure 2. Combined Workflow for the QuantideX®qPCR ESR1 exoMutation Kit and ExoLution Plus cfDNA and exoRNA Isolation Kit. Note: Hands-on time will vary depending on the number of samples being run. The above is based on 6 samples.

 

Variant Detection as Low as 0.025% VAF*

Figure 3. Probit analysis of synthetic DNA (0, 1, 3, 5, 10 copies/reaction, 20 replicates of each) titrated in a background of presumed normal DNA (10,000 total copies). *ABI QuantStudio 5 Dx.

High Analytical Specificity Across K₂EDTA and PAXgene Tubes

Figure 4. Evaluation of target analytical specificity (exclusivity) was determined on plasma procured from presumed normal samples.

 

Optimising Data Reporting with Automated Software Features

The QuantideX®qPCR ESR1 exoMutation Kit’s ready-to-use design doesn’t stop at the bench. The push-button, automated software, created to run on commonly used operating systems, takes the guesswork and hands-on time out of data analysis. The software module is included with the assay and does not require separate purchases or licenses.

Software Enabling Comprehensive, Push-Button Analysis and QC QuantideX® qPCR ESR1 exoMutation Analysis Module

  • Automated variant calling
  • Batch Control QCs
  • Click on the “+” on the left side of table to drill down to Ct (Cq) values
  • Export results in LIMS-compatible format (CSV)

 

Supporting Sensitive ESR1 Mutation Research

The QuantideX® qPCR ESR1 exoMutation Kit combines cfDNA and exosomal RNA analysis with established qPCR technology to support sensitive detection of ESR1 mutations in plasma. With an integrated isolation workflow, detection of 11 prevalent ESR1 variants and automated data analysis, it offers molecular laboratories a streamlined approach to investigating endocrine therapy resistance in metastatic breast cancer research.

Interested in learning more about the QuantideX® qPCR ESR1 exoMutation Kit? Fill in the form below for more details about the assay, its workflow and how it could support your laboratory’s breast cancer research applications.

 

 

Further resources

Monitoring ESR1 Mutations in Metastatic Breast Cancer

Understanding ESR1 Mutations in Metastatic Breast Cancer – Testing and Implications Guide

QuantideX® qPCR ESR1 exoMutation Kit Protocol Guide

QuantideX® qPCR ESR1 exoMutation Analysis Module Version 1.0 Software User Guide

ExoLution™ Plus cfDNA + exoRNA Isolation Kit Protocol Guide

Enquire about this product

"*" indicates required fields